Cannabinoid Receptor Antagonists Counteract Sensorimotor Gating Deficits in the Phencyclidine Model of Psychosis-Reference-Cited by-同舟云学术

Cannabinoid Receptor Antagonists Counteract Sensorimotor Gating Deficits in the Phencyclidine Model of Psychosis

Published:2007-02-14 Issue:10 Volume:32 Page:2098-2107
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol

Author:

Ballmaier Martina,Bortolato Marco,Rizzetti Cristina,Zoli Michele,Gessa GianLuigi,Heinz Andreas,Spano PierFranco

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/1301344.pdf

Reference81 articles.

1. Auclair N, Otani S, Soubrie P, Crepel F (2000). Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses. J Neurophysiol 83: 3287–3293.

2. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, Rammes G (2003). Activation of the cannabinoid receptor type 1 decreases glutamate and GABAergic synaptic transmission in the lateral amygdale of the mouse. Learn Memory 10: 116–128.

3. Bakshi VP, Geyer MA (1995). Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122: 198–201.

4. Bakshi VP, Swerdlow NR, Geyer MA (1994). Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 27: 787–794.

5. Ballmaier M, Casamenti F, Scali C, Mazzoncini R, Zoli M, Pepeu G et al (2002). Rivastigmine antagonizes deficts in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Neuroscience 114: 91–98.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic‐like activity of cannabidiolic acid methyl ester in the MK‐801 mouse model of schizophrenia: Role for cannabinoid CB1 and serotonin‐1A receptors;European Journal of Neuroscience;2024-02-22

2. Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders;International Journal of Molecular Sciences;2022-04-26

3. Targeting Endocannabinoid System in Epilepsy: For Good or for Bad;Neuroscience;2022-02

4. From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia;Frontiers in Psychiatry;2021-07-05

5. Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis;Psychopharmacology;2021-01-26